| Literature DB >> 27032515 |
Andrew C Steer1, Jonathan R Carapetis2, James B Dale3, John D Fraser4, Michael F Good5, Luiza Guilherme6, Nicole J Moreland7, E Kim Mulholland8, Florian Schodel9, Pierre R Smeesters10.
Abstract
Streptococcus pyogenes is an important global pathogen, causing considerable morbidity and mortality, especially in low and middle income countries where rheumatic heart disease and invasive infections are common. There is a number of promising vaccine candidates, most notably those based on the M protein, the key virulence factor for the bacterium. Vaccines against Streptococcus pyogenes are considered as impeded vaccines because of a number of crucial barriers to development. Considerable effort is needed by key players to bring current vaccine candidates through phase III clinical trials and there is a clear need to develop a roadmap for future development of current and new candidates.Entities:
Keywords: Group A Streptococcus; Rheumatic fever; Streptococcus pyogenes; Vaccine
Mesh:
Substances:
Year: 2016 PMID: 27032515 DOI: 10.1016/j.vaccine.2016.03.073
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641